CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

KRAS 突变型胰腺癌免疫治疗的最新进展

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.

胰腺导管腺癌免疫治疗的现状与未来展望

Current status and future prospects of immunotherapy for pancreatic ductal adenocarcinoma.

溶瘤腺病毒联合 PD-L1 靶向放射免疫疗法对胰腺癌产生协同抗肿瘤效应

Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer.

我们的研究结果表明，HY-oAd 能以多方面的方式增强 177 Lu-aPD-L1 在肿瘤内的积聚，从而激发针对促结缔组织增生性和免疫原性差的胰腺肿瘤的协同抗肿瘤免疫反应。

用 CXCL-11、IL-12 和抗 PD-1 单链抗体武装溶瘤单纯疱疹病毒以增强胰腺导管腺癌 CAR-T 细胞治疗

Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal

放疗作为胰腺癌免疫治疗的伙伴：当前格局与未来方向

Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.

携带 IL-12 的溶瘤 HSV-2 增强 CAR-T 细胞在异种移植模型中对胰腺癌的疗效

IL-12-armed oncolytic HSV-2 enhances CAR T cell efficacy against pancreatic cancer in xenografted models.

这种协同策略以降低的 CAR-T 剂量实现了持久而强效的肿瘤清除，为胰腺癌及其他具有挑战性的实体恶性肿瘤提供了一种变革性策略。

基因治疗：改变对抗胰腺癌的战局

Gene Therapy: Transforming the Battle Against Pancreatic Cancer.

一种携带 CD47 纳米抗体的新型溶瘤痘病毒通过重塑免疫微环境治疗胰腺癌

A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.

溶瘤腺病毒免疫治疗增强同种异体过继 HER2.CAR-NK 抗胰腺导管腺癌功能

Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma.